ClearPoint Neuro CLPT Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net

Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net at other companies

ITG

Integer HoldingsITGR

——

Other financials

Income statement

See full

Revenue$12.1M+42.9%

Gross profit$7.8M+51.1%

Operating income-$8.5M-37.6%

Net income-$9.6M-58.5%

EPS (diluted)-$0.32-45.5%

Balance sheet

See full

Cash & equivalents$36.5M+195%

Total debt$63.6M+1,750%

Total equity$18.8M-5.7%

Total assets$93.4M+211%

Cash flow

See full

Operating cash flow-$8.0M-29.1%

CapEx$645.0K+252%

Free cash flow-$8.6M-35.5%

Valuation

See full

Market cap$538.61M+69.2%

Enterprise value$565.68M+82.9%

P/S13.3×+3.4×

Profitability

See full

Gross margin62.3%+1.1pp

Operating margin-65.2%-1.9pp

Net margin-71.6%+8.8pp

FCF margin-65.7%+269pp

Returns & leverage

See full

Return on equity-149.7%+4,074pp

Debt / equity3.4×+3.2×

Current ratio5.8×+2.3×

Where this comes from

Reported directly by ClearPoint Neuro in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet.

The official record: ClearPoint Neuro’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about ClearPoint Neuro's debt instrument, unamortized discount (premium) and debt issuance costs, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ClearPoint Neuro's debt instrument, unamortized discount (premium) and debt issuance costs, net?: ClearPoint Neuro (CLPT) reported debt instrument, unamortized discount (premium) and debt issuance costs, net of $1.79M in Q1 2026.